Tscan therapeutics provides clinical pipeline update and highlights near-term priorities

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one tcr-t in the immunobank and ~30% are eligible for multiplex therapy
TCRX Ratings Summary
TCRX Quant Ranking